CSW

SEC source: 0001624794-21-000068 · wf-form4_162923253390395.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,571

F1 · kind: Reflects the broker-assisted cashless exercise and sale of non qualified stock options.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.05 to $130.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000068 · wf-form4_162923253390395.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Reflects the broker-assisted cashless exercise and sale of non qualified stock options.

SEC source: 0001624794-21-000069 · wf-form4_162923261482079.xml · nonDerivative · entry 1

GAMBRELL MICHAEL R · CIK 0001277031 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,403

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $129.33 to $130.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001624794-21-000047 · wf-form4_162646646317090.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,481

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.33 to $114.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000047 · wf-form4_162646646317090.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,781

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.32 to $114.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000045 · wf-form4_162387683876177.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,481

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.00 to $116.87, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000045 · wf-form4_162387683876177.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,481

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.78 to $115.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000038 · wf-form4_162197463526504.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,481

F1 · kind: Represents shares donated by the Reporting Person to a charitable donor advised fund.

SEC source: 0001624794-21-000024 · wf-form4_162129034587212.xml · nonDerivative · entry 3

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,981

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.00 to $127.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000024 · wf-form4_162129034587212.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,083

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.88 to $126.86, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000024 · wf-form4_162129034587212.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,881

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

SEC source: 0001624794-21-000022 · wf-form4_161947299904123.xml · derivative · entry 4

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,685

Underlying: Common Stock · 19,685 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.

F5 · price: Represents performance-conditioned restricted stock units granted to the reporting person pursuant to the issuer's Equity and Incentive Compensation Plan as part of a three-part special long-term incentive award with the objectives of retention through retirement and successful succession planning and transition practices.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at vesting. 40% of the restricted stock units vest no earlier than April 26, 2025 upon the successful recruitment and hiring of a successor Chief Executive Officer; the remaining 60% vest upon the successful first employment anniversary of a successor Chief Executive Officer.

SEC source: 0001624794-21-000022 · wf-form4_161947299904123.xml · derivative · entry 3

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,559

Underlying: Common Stock · 27,559 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest in three equal amounts, at a rate between 0% and 200%, during three performance cycles beginning on April 1, 2021 and ending on each of March 31, 2025, March 31, 2026 and March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the relevant performance cycle. The performance rights may be settled, at the issuers discretion, in cash or shares of common stock.

F3 · price: Represents performance shares granted to the reporting person pursuant to the issuer's Equity and Incentive Compensation Plan as part of a three-part special long-term incentive award with the objectives of retention through retirement and successful succession planning and transition practices.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest in three equal amounts, at a rate between 0% and 200%, during three performance cycles beginning on April 1, 2021 and ending on each of March 31, 2025, March 31, 2026 and March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the relevant performance cycle. The performance rights may be settled, at the issuers discretion, in cash or shares of common stock.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest in three equal amounts, at a rate between 0% and 200%, during three performance cycles beginning on April 1, 2021 and ending on each of March 31, 2025, March 31, 2026 and March 31, 2027 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the relevant performance cycle. The performance rights may be settled, at the issuers discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000022 · wf-form4_161947299904123.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,981

F1 · price: Represents shares of restricted common stock granted to the reporting person pursuant to the issuer's Equity and Incentive Compensation Plan as part of a three-part special long-term incentive award with the objectives of retention through retirement and successful succession planning and transition practices. The shares cliff vest on the fifth anniversary of the grant date.

SEC source: 0001624794-21-000020 · wf-form4_161858693690726.xml · nonDerivative · entry 3

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,485

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.67 to $139.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000020 · wf-form4_161858693690726.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,785

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.30 to $138.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000020 · wf-form4_161858693690726.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,385

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

SEC source: 0001624794-21-000013 · wf-form4_161774608332319.xml · derivative · entry 4

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,980

Underlying: Common Stock · 1,135 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000013 · wf-form4_161774608332319.xml · derivative · entry 3

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,845

Underlying: Common Stock · 2,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000013 · wf-form4_161774608332319.xml · nonDerivative · entry 2

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,168

SEC source: 0001624794-21-000013 · wf-form4_161774608332319.xml · nonDerivative · entry 1

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001624794-21-000014 · wf-form4_161774623145622.xml · derivative · entry 5

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,860

Underlying: Common Stock · 6,154 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000014 · wf-form4_161774623145622.xml · derivative · entry 4

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,706

Underlying: Common Stock · 15,554 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000014 · wf-form4_161774623145622.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,485

SEC source: 0001624794-21-000014 · wf-form4_161774623145622.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,885

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001624794-21-000015 · wf-form4_161774637771765.xml · derivative · entry 1

Perry James E · CIK 0001323684 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,929

Underlying: Common Stock · 2,650 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000017 · wf-form4_161774664054683.xml · derivative · entry 3

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,364

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F1 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000017 · wf-form4_161774664054683.xml · nonDerivative · entry 2

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,522

SEC source: 0001624794-21-000017 · wf-form4_161774664054683.xml · nonDerivative · entry 1

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001624794-21-000016 · wf-form4_161774650376394.xml · derivative · entry 4

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,980

Underlying: Common Stock · 2,147 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F2 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F2 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000016 · wf-form4_161774650376394.xml · derivative · entry 3

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,127

Underlying: Common Stock · 3,029 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000016 · wf-form4_161774650376394.xml · nonDerivative · entry 2

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,037

SEC source: 0001624794-21-000016 · wf-form4_161774650376394.xml · nonDerivative · entry 1

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,593

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001624794-21-000019 · wf-form4a_161780235628883.xml · derivative · entry 3

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,364

Underlying: Common Stock · 3,207 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F2 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F2 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000019 · wf-form4a_161780235628883.xml · nonDerivative · entry 2

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,040

F1 · balance_after: This Amendment to Form 4 does not report a new transaction. This Amendment is being filed solely to correct an inadvertent mathematical error in the sum reported for the Amount of Securities Beneficially Owned following the transactions previously reported in the original Form 4 filed on April 6, 2021.

SEC source: 0001624794-21-000019 · wf-form4a_161780235628883.xml · nonDerivative · entry 1

Foster Craig James · CIK 0001663184 · SVP & GM, Spec. Chem.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Amendment to Form 4 does not report a new transaction. This Amendment is being filed solely to correct an inadvertent mathematical error in the sum reported for the Amount of Securities Beneficially Owned following the transactions previously reported in the original Form 4 filed on April 6, 2021.

SEC source: 0001624794-21-000018 · wf-form4a_161780232778703.xml · derivative · entry 4

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,980

Underlying: Common Stock · 2,147 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F3 · derivative.exercise_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

F3 · derivative.expiration_date: Each performance right represented a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vested at a rate between 0% and 200% during a three-year performance cycle ending on March 31, 2021 based on the issuer's relative total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights, along with accrued dividend equivalent units, vested at 200% of the target award amount and were settled in shares of common stock pursuant to the award agreement terms.

SEC source: 0001624794-21-000018 · wf-form4a_161780232778703.xml · derivative · entry 3

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,127

Underlying: Common Stock · 3,029 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of the issuer's common stock at vesting. The performance rights vest at a rate between 0% and 200% during a three-year performance cycle beginning on April 1, 2021 and ending on March 31, 2024 based on the issuer's relative total shareholder return in comparison to the total shareholder return performance among the Russell 2000 Index over the performance cycle. The performance rights may be settled, at the issuer's discretion, in cash or shares of common stock.

SEC source: 0001624794-21-000018 · wf-form4a_161780232778703.xml · nonDerivative · entry 2

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,403

F1 · balance_after: This Amendment to Form 4 does not report a new transaction. This Amendment is being filed solely to correct an inadvertent mathematical error in the sum reported for the Amount of Securities Beneficially Owned following the transactions previously reported in the original Form 4 filed on April 6, 2021.

SEC source: 0001624794-21-000018 · wf-form4a_161780232778703.xml · nonDerivative · entry 1

Sullivan Don · CIK 0001663176 · SVP & GM, Ind. Products

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This Amendment to Form 4 does not report a new transaction. This Amendment is being filed solely to correct an inadvertent mathematical error in the sum reported for the Amount of Securities Beneficially Owned following the transactions previously reported in the original Form 4 filed on April 6, 2021.

SEC source: 0001624794-21-000012 · wf-form4_161585187462356.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,311

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.41 to $135.38, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000012 · wf-form4_161585187462356.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,811

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.33 to $134.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000011 · wf-form4_161524571509720.xml · nonDerivative · entry 2

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,781

F1 · kind: Represents shares donated by the Reporting Person to a charitable donor advised fund.

SEC source: 0001624794-21-000011 · wf-form4_161524571509720.xml · nonDerivative · entry 1

Alverson Luke · CIK 0001668461 · SVP, GC & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,168

SEC source: 0001624794-21-000010 · wf-form4_161359799529010.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,311

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.38 to $130.10, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000010 · wf-form4_161359799529010.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,166

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.37 to $129.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000001 · wf-form4_161075070168928.xml · nonDerivative · entry 4

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,311

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.06 to $125.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000001 · wf-form4_161075070168928.xml · nonDerivative · entry 3

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,321

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.05 to $124.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000001 · wf-form4_161075070168928.xml · nonDerivative · entry 2

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,411

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.01 to $123.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001624794-21-000001 · wf-form4_161075070168928.xml · nonDerivative · entry 1

Armes Joseph B · CIK 0001413614 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,811

F1 · kind: The transaction reported was effected pursuant to a 10b5-1 trading plan established by the reporting person on August 15, 2019.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.005 to $122.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.